visceral fat semaglutide Effects of liraglutide on abdominal distribution and glucose metabolism in Chinese subjects with obesity | Diabetology & Metabolic Syndrome Will I Lose Belly Fat

Doctors can guide them in finding a balance between safety, how well it works, and cost

#GLP1 #SustainableWeightLoss #IntegrativeMedicine The GLP-1 revolution isn't just about medicationsit's about integration

Retatrutide will likely be integrated into this framework, with initial access prioritized for: Cohort I (2025-2028): Patients with a BMI and four or more qualifying comorbidities (hypertension, dyslipidemia, OSA, CVD, or T2DM)

Patients should not stop antihypertensive medications without clinical input

Whether you choose to use these GLP-1 agonists is a personal choice and a discussion that you should have with your family and your doctor